Tradestie Institutional Equity Comparison Engine

SYRE vs IONS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SYRE Overall Edge

SYRE Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Spyre Therapeutics, Inc. Common Stock (SYRE) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while IONS counters with relative strength in Valuation. Fundamentally, SYRE trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus IONS at 90.9x Forward P/E and -58.8% operating margin (+54.9% YoY). In options structure, SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro) against IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner IONS
SYRE N/M vs IONS 90.9x Fwd P/E
Growth & Margin Winner SYRE
Op Margin 0.0% vs -58.8% ยท YoY +0.0% vs +54.9%
Momentum & Technical Winner SYRE
1Y +341.7% vs -59.1% ยท 52W Pos 88% vs 2%
Options & Structure Winner SYRE
UNCLASSIFIED (10th %ile IV) vs BREAKDOWN (17th %ile IV)
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
1M Return +25.11%
1Y Return +341.74%
Forward P/E N/M
Unified AI Score
36.1 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
1M Return -33.48%
1Y Return -59.1%
Forward P/E 90.9x
Unified AI Score
60.4 / 100 BUY
Tech 60.0 Fund 62.0 Flow 73.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SYRE +341.74% IONS -59.1% Spread: +400.84 pp (SYRE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SYRE TTM Op. Margin: 0.0% IONS TTM Op. Margin: -58.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs IONS. Trailing 12-month operating profitability (SYRE 0.0% vs IONS -58.8%) and valuation multiples (SYRE N/M vs IONS 90.9x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SYRE (6) vs IONS (4)
Institutional Metric SYRE IONS Criterion Row Winner
Market Capitalization Scale $9.8B $4.7B Larger Scale SYRE
Trailing P/E Ratio Valuation N/M 90.9x Lower Multiple IONS
Forward P/E Ratio Valuation N/M 90.9x Lower Multiple IONS
Revenue Growth (YoY) Growth +0.0% +54.9% Higher Growth IONS
Operating Margin (TTM) Profitability 0.0% -58.8% Higher Margin SYRE
Net Profit Margin Profitability 0.0% -56.9% Higher Margin SYRE
Return on Equity (ROE) Capital Efficiency -35.0% -108.0% Higher ROE SYRE
52-Week Range Position Momentum 88% ($22โ€“$111) 2% ($27โ€“$87) Stronger Trend SYRE
Beta / 30D Volatility Risk Regime 1.75ฮฒ ยท 59% Vol 0.18ฮฒ ยท 86% Vol Lower Realized Risk SYRE
Unified Institutional Score Composite Signal 36.1 / 100 (SELL) 60.4 / 100 (BUY) Higher Composite IONS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SYRE vs IONS Buy Guide
SYRE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live SYRE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IONS BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live IONS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SYRE nor IONS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.